Skip to main content
. Author manuscript; available in PMC: 2017 May 2.
Published in final edited form as: Pharmacol Res. 2016 Nov 16;115:87–95. doi: 10.1016/j.phrs.2016.11.014

Figure 3. Performance of passively and actively targeted nanomedicines.

Figure 3

A. Survival benefit obtained using PEGylated liposomal doxorubicin (Doxil) as compared to topotecan in patients suffering from ovarian cancer (35). B. Phase I results obtained using BIND-014, a docetaxel-loaded polymeric nanoparticle actively targeted to the prostate-specific membrane antigen (PSMA; which is overexpressed on prostate cancer cells and also on activated endothelium), showing the regression of lung metastases via CT scans (52). C. HER2-antibody-targeted liposomes are taken up much more strongly by cancer cells in vitro than antibody-free liposomes (inset), but this does not result in improved tumor accumulation in vivo (54). D-E. Accumulation of radiolabeled liposomes in tumors in patients, showing a relatively high degree of EPR-mediated accumulation in sarcomas (D), and a more moderate accumulation in breast cancer (E). Tu: tumor, LN: lymph node, L: liver, Spl: spleen (61, 62).